REFERENCES
- Panigrahi A, Gupta N, Siddiqui JA, Post transplant development of MICA and anti-HLA antibodies is associated with acute rejection episodes and renal allograft loss. Hum Immunol. 2007;68:362–367.
- Kerman RH, Susskind B, Buelow R, Correlation of ELISA-detected IgG and IgA anti-HLA antibodies in pretransplant sera with renal allograft rejection. Transplantation. 1996;62:201–205.
- Feucht HE, Opelz G. The humoral immune response towards HLA class II determinants in renal transplantation (editorial). Kidney Int. 1996;50:1464–1475.
- Claas FHJ, Doxiadis IIN. Management of the highly sensitized patient. Curr Opin Immunol. 2009;21:1–4.
- Doxiadis IIN, Claas FHJ. Transplantation of highly sensitized patients via the acceptable mismatch program or desensitization? We need both? Curr Opin Organ Transplant. 2009;14:410–413.
- Heinemann FM, Roth I, Rebmann V, Immunoglobulin isotype specific characterization of anti-human leukocyte antigen antibodies eluted from explanted renal allografts. Hum Immunol. 2007;68:500–506.
- Terasaki PI. Humoral theory of transplantation. Am J Transplant. 2003;3:665–673.
- Sumitran-Holgersson S. HLA specific alloantibodies and renal graft outcome. Nephrol Dial Transplant. 2001;16:897–904.
- Ionescu DN, Girnita AL, Zeevi A, C4d deposition in lung allografts is associated with circulating anti-HLA antibody. Transpl Immunol. 2005;15:63–68.
- Lieber SR, Perez FVT, Tabossi MR, Effect of panel reactive antibody in predicting crossmatch selection of cadaveric kidney recipients. Transplant Proc. 2007;39:429–431.
- Yang CW, Oh EJ, Lee SB, Detection of donor specific anti-HLA class I and II antibodies using antibody monitoring system. Transplant Proc. 2006;38:2803–2806.
- Panigrahi A, Deka R, Bhowmik D, Tiwari SC, Mehra NK. Immunological monitoring of posttransplant allograft sensitization following living related donor renal transplantation. Transplant Proc. 2004;36:1336–1339.
- Heise E, Manning C, Thacker L. HLA phenotypes of ESRD patients are risk factors in the panel reactive antibody response. Clin Transplant. 2001;15:22–27.
- Stobbe I, van der Meer-Prins E, Smits JMA, Doxiadis IIN, Claas FHJ. In vitro reactivity of allospecific cytotoxic T lymphocytes does not explain the taboo phenomenon. Transpl Immunol. 1999;7:215–220.
- Terasaki PI, McClelland JD. Microdroplet assay of human serum cytotoxins. Nature. 1964;204:998.
- Olerup O, Zetterquist H. HLA-DR typing by PCR amplification with sequence-specific primers (PCR-SSP) in two hours: An alternative to serological DR typing in clinical practice including donor-recipient matching in cadaveric transplantation. Tissue Antigens. 1992;39:225.
- Claas FHJ, van Rood JJ. The hyperimmunized patient: From sensitization toward transplantation. Transpl Int. 1988;1:53–57.
- Patel R, Terasaki PI. Significance of the positive crossmatch test in kidney transplantation. N Engl J Med. 1969 2;80:735–739.
- Papassavas AC, Barnardo MC, Bunce M, Welsh KI. Is there MHC Class II restriction of the response to MHC Class I in transplant patients? Transplantation. 2002;73:642–651.
- Kreisler JM, Rementeria MC, De Pablo R, Moreno ME. HLA-DR2, a marker for class I antigen sensitization. Transplantation. 1988;45:1071–1074.
- Fuller TC, Fuller A. The humoral immune response against an HLA class I allodeterminant correlates with the HLA-DR phenotype of the responder. Transplantation. 1999;68:173–182.
- Cicciarelli J. HLA-DR1 low responsiveness antigen in human kidney transplant recipients. Clinical Transpl. 1987;381–391.